By Entea, a healthcare provider specializing in psychedelic therapy, announced on Tuesday The company will launch in 40 markets across the United States next year, expanding Encia’s customer base and provider network to bring affordable, safe and effective psychedelic support therapy access to all who benefit from it. Advancing our mission to provide.
The ambitious launch is an outgrowth of a “successful $2 million seed funding round led by Tabula Rasa Ventures, the first psychedelic accelerator for early-stage startups,” the company announced. said in
Enthea says the impetus for this new effort is to improve access to potentially groundbreaking psychedelic treatments amid an ever-growing mental health crisis in the United States.
The company claims it is “supporting this mental health crisis by providing employer funding for these new treatments,” adding that “traditional health insurers are doing what they can to add this coverage.” It’s been taking years, and the cost to patients is preventing widespread adoption.”
Enthea CEO and Co-Founder Sherry Rais said: statement on Tuesday. “And as a workplace benefit, this treatment will be affordable. will be.”
The newly announced project has been around for years. In a press release on Tuesday, Enthea said it had “spent the past two years building the infrastructure necessary to scale this concept and bring it to market,” and that next month it will “expand new markets in New York City, Austin, and the Bay Area.” The area aims to open in the top 20 cities in the U.S. by mid-2023, with an additional 20 cities by the end of 2023.”
The company said, “To provide this psychedelic therapy as a workplace benefit… [it] We have developed several core competencies”:
- Evidence-based medical policies for psychedelic therapies that are updated regularly based on clinical development and FDA approval.
- Standards of care and qualifications across the Enthea provider network ensure quality, positive patient experiences and positive treatment outcomes.
- Easy treatment authorization and reimbursement to providers while protecting employers from protected health information.
- A range of customizable options based on your company’s business and HR needs.
Enthea is dedicated to providing “safe and affordable access to these innovative and effective treatments” and is licensed for health insurance benefits covering “psychedelic assisted psychotherapy (PAP).” Provider”.
Earlier this year, the company partnered with Dr. Bronner to make the soap maker “the first employer to add ketamine-assisted psychotherapy to their existing health insurance plan.”
“Many members of the Dr. Bronner All-One family who have struggled with mental health challenges have taken advantage of ketamine-supported therapy and expressed their sincere appreciation for the incredible healing benefits it has provided,” said David. Bronner said Dr. Bronner’s CEO. “Enthea has provided a seamless experience for our staff as well as our side. I can’t recommend his Enthea highly enough. I hope everyone who needs help , may you benefit from this healing potion and therapy!”
Bronner is an outspoken advocate of psychedelic therapy. In a press release this week, Entea said the two companies “share a common belief that psychedelic-assisted therapies have become accepted into the standard of healthcare and have tremendous potential to not only improve quality of life, but to heal.” ‘ said.
“To be honest, the world would be a much better place if more people experienced psychedelic drugs.” bronner said new york times.
